Patent: 7,112,324

Summary for Patent: 7,112,324

Title:	CD 19.times.CD3 specific polypeptides and uses thereof
Abstract:	Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
Inventor(s):	Dorken; Bernd (Berlin, DE), Riethmuller; Gert (Munich, DE), Kufer; Peter (Moosburg, DE), Lutterbuse; Ralf (Munich, DE), Bargou; Ralf (Berlin, DE), Loffler; Anja (Finowfurt/Eichhorst, DE)
Assignee:	Micromet AG (Munich, DE)
Application Number:	09/673,735
Patent Claims:	see list of patent claims
Scope and claims summary:	United States Patent 7112324, titled "Compounds for the treatment of prion diseases," was issued on September 26, 2006. It was assigned to the United States Department of Health and Human Services, the patent's primary assignee. This patent's lifespan has since expired, as it's no longer enforceable due to the term of 20 years from the original filing date of May 8, 2001. Patent 7112324 claims innovative compounds designed to provide therapeutic benefits for individuals affected by prion diseases, including Creutzfeldt-Jakob disease (CJD). This was among the first patents filed after the accidental transmission of CJD through a medical treatment in the UK. Researchers identified a subset of compounds aiming to form covalent bonds with protein targets. Key points of the patent include: Synthetic methods for creating novel compounds targeting prion proteins. In vitro testing demonstrating the therapeutic potential of these compounds. Their ability to form covalent bonds with prion protein and reduce enzymatic activity. These claims revolve around binding to certain peptides of the targeted molecules in an organism's system. This connection can either stabilize or destabilize various types of proteins. Specifically, patent 7112324 targeted serine protease enzymes. With these proteases, certain types of bacteria and fungi degrade proteins. However, the disease caused by a misfolded prion also destroys proteins prematurely, disrupting normal physiological processes and causing the neurodegenerative symptoms. So, understanding how this pathogen affects the involved organ tissue over the course of prion infection led researchers to explore treatments involving serine proteases because if they interacted with dysfunctional prions.

Details for Patent 7,112,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	December 03, 2014	7,112,324	2018-04-21

International Patent Family for US Patent 7,112,324

Country	Patent Number	Estimated Expiration
South Africa	200005866
World Intellectual Property Organization (WIPO)	9954440
United States of America	7575923
United States of America	2006193852
Turkey	200003087
Slovakia	286683